

**DRAFT
TOXICOLOGICAL PROFILE FOR
COBALT**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry**

September 2001

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. We plan to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Comments should be sent to:


Agency for Toxic Substances and Disease Registry
Division of Toxicology
1600 Clifton Road, N.E.
Mail Stop E-29
Atlanta, Georgia 30333

The toxicological profiles are developed in response to the Superfund Amendments and

Background Information

The toxicological profiles are developed by ATSDR pursuant to Section 104(i) (3) and (5) of the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund) for hazardous substances found at Department of Energy (DOE) waste sites. CERCLA directs ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. ATSDR and DOE entered into a Memorandum of Understanding on November 4, 1992 which provided that ATSDR would prepare toxicological profiles for hazardous substances based upon ATSDR's or DOE's identification of need. The current ATSDR priority list of hazardous substances at DOE NPL sites was announced in the Federal Register on July 24, 1996 (61 FR 38451).

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Jeffrey P. Koplan, M.D., M.P.H.
Administrator
Agency for Toxic Substances and
Disease Registry

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by *route of exposure*, by *type of health effect* (death, systemic, immunologic, reproductive), and by *length of exposure* (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

Section 1.7	How Can (Chemical X) Affect Children?
Section 1.8	How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.6	Children's Susceptibility
Section 6.6	Exposures of Children

Other Sections of Interest:

Section 3.7	Biomarkers of Exposure and Effect
Section 3.10	Methods for Reducing Toxic Effects

ATSDR Information Center

Phone: 1-888-42-ATSDR or (404) 498-0110

Fax: (404) 498-0057

E-mail: atsdric@cdc.gov

Internet: <http://www.atsdr.cdc.gov>

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards*; *Skin Lesions and Environmental Exposures*; *Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. *Contact:* NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. *Contact:* NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. *Contact:* NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. *Contact:* AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. *Contact:* ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-818-1800 • FAX: 847-818-9266.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS(S):

Obaid M. Faroon, D.V.M., Ph.D.
Henry Abadin, M.S.P.H.
Sam Keith, M.S., C.H.P.
ATSDR, Division of Toxicology, Atlanta, GA

Mark Osier, Ph.D.
Gary Diamond, Ph.D.
Gloria Sage, Ph.D.
Syracuse Research Corporation, North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.

PEER REVIEW

A peer review panel was assembled for cobalt. The panel consisted of the following members:

1. Dr. Herman Cember, C.H.P., Ph.D., PE., Adjunct Professor, School of Health Sciences, Purdue University, Lafayette, Indiana;
2. Dr. James Hansen, Ph.D., Senior Associate, Stratus Consulting Inc., Longmont, CO;
3. Dr. Dominique Lison, M.D., Ph.D., Vice-Chairman of the Doctoral School in Genetics and Immunology, Catholic University of Louvain, Brussels, Belgium;
4. Dr. Nancy Pedigo, Ph.D., Research Assistant Professor, Department of Pharmacology, University of Kentucky Medical Center, Lexington, KY.

These experts collectively have knowledge of cobalt's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS	vii
CONTRIBUTORS	xi
PEER REVIEW	xiii
LIST OF FIGURES	xix
LIST OF TABLES	xxi
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT IS COBALT?	1
1.2 WHAT HAPPENS TO COBALT WHEN IT ENTERS THE ENVIRONMENT?	3
1.3 HOW MIGHT I BE EXPOSED TO COBALT?	5
1.4 HOW CAN COBALT ENTER AND LEAVE MY BODY?	7
1.5 HOW CAN COBALT AFFECT MY HEALTH?	7
1.6 HOW CAN COBALT AFFECT CHILDREN?	11
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO COBALT?	11
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO COBALT?	12
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	12
1.10 WHERE CAN I GET MORE INFORMATION?	13
2. RELEVANCE TO PUBLIC HEALTH	15
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO COBALT IN THE UNITED STATES	15
2.2 SUMMARY OF HEALTH EFFECTS	16
2.3 MINIMAL RISK LEVELS	22
3. HEALTH EFFECTS	27
3.1 INTRODUCTION	27
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	27
3.2.1 Inhalation Exposure	29
3.2.1.1 Death	29
3.2.1.2 Systemic Effects	41
3.2.1.3 Immunological and Lymphoreticular Effects	49
3.2.1.4 Neurological Effects	49
3.2.1.5 Reproductive Effects	50
3.2.1.6 Developmental Effects	50
3.2.1.7 Cancer	50
3.2.2 Oral Exposure	52
3.2.2.1 Death	52
3.2.2.2 Systemic Effects	68
3.2.2.3 Immunological and Lymphoreticular Effects	75
3.2.2.4 Neurological Effects	76

3.2.2.5	Reproductive Effects	76
3.2.2.6	Developmental Effects	77
3.2.2.7	Cancer	78
3.2.3	Dermal Exposure	78
3.2.3.1	Death	78
3.2.3.2	Systemic Effects	78
3.2.3.3	Immunological and Lymphoreticular Effects	79
3.2.3.4	Neurological Effects	81
3.2.3.5	Reproductive Effects	81
3.2.3.6	Developmental Effects	81
3.2.3.7	Cancer	81
3.2.4	External Exposure	81
3.2.4.1	Death	97
3.2.4.2	Systemic Effects	98
3.2.4.3	Immunological and Lymphoreticular Effects	102
3.2.4.4	Neurological Effects	103
3.2.4.5	Reproductive Effects	104
3.2.4.6	Developmental Effects	105
3.2.4.7	Cancer	107
3.3	GENOTOXICITY	107
3.4	TOXICOKINETICS	113
3.4.1	Absorption	113
3.4.1.1	Inhalation Exposure	113
3.4.1.2	Oral Exposure	115
3.4.1.3	Dermal Exposure	118
3.4.2	Distribution	118
3.4.2.1	Inhalation Exposure	119
3.4.2.2	Oral Exposure	119
3.4.2.3	Dermal Exposure	120
3.4.2.4	Other Routes of Exposure	120
3.4.3	Metabolism	121
3.4.4	Elimination	121
3.4.4.1	Inhalation Exposure	121
3.4.4.2	Oral Exposure	122
3.4.4.3	Dermal Exposure	124
3.4.4.4	Other Routes of Exposure	125
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	127
3.5	MECHANISMS OF ACTION	142
3.5.1	Pharmacokinetic Mechanisms	142
3.5.2	Mechanisms of Toxicity	144
3.5.3	Animal-to-Human Extrapolations	147
3.6	ENDOCRINE DISRUPTION	148
3.7	CHILDREN'S SUSCEPTIBILITY	150
3.8	BIOMARKERS OF EXPOSURE AND EFFECT	153
3.8.1	Biomarkers Used to Identify or Quantify Exposure to Cobalt	154
3.8.2	Biomarkers Used to Characterize Effects Caused by Cobalt	157
3.9	INTERACTIONS WITH OTHER CHEMICALS	157
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	158
3.11	METHODS FOR REDUCING TOXIC EFFECTS	159
3.11.1	Reducing Peak Absorption Following Exposure	160

3.11.2	Reducing Body Burden	160
3.11.3	Interfering with the Mechanism of Action for Toxic Effects	161
3.12	ADEQUACY OF THE DATABASE	161
3.12.1	Existing Information on Health Effects of Cobalt	161
3.12.2	Identification of Data Needs	164
3.12.3	Ongoing Studies	173
4.	CHEMICAL AND PHYSICAL INFORMATION	175
4.1	CHEMICAL IDENTITY	175
4.2	PHYSICAL, CHEMICAL, AND RADIOLOGICAL PROPERTIES	175
5.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	185
5.1	PRODUCTION	185
5.2	IMPORT/EXPORT	191
5.3	USE	191
5.4	DISPOSAL	193
6.	POTENTIAL FOR HUMAN EXPOSURE	197
6.1	OVERVIEW	197
6.2	RELEASES TO THE ENVIRONMENT	202
6.2.1	Air	206
6.2.2	Water	207
6.2.3	Soil	209
6.3	ENVIRONMENTAL FATE	210
6.3.1	Transport and Partitioning	210
6.3.2	Transformation and Degradation	216
6.3.2.1	Air	216
6.3.2.2	Water	217
6.3.2.3	Sediment and Soil	218
6.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	220
6.4.1	Air	220
6.4.2	Water	220
6.4.3	Sediment and Soil	227
6.4.4	Other Environmental Media	230
6.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	236
6.6	EXPOSURES OF CHILDREN	244
6.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	245
6.8	ADEQUACY OF THE DATABASE	246
6.8.1	Identification of Data Needs	247
6.8.2	Ongoing Studies	250
7.	ANALYTICAL METHODS	253
7.1	BIOLOGICAL SAMPLES	253
7.1.1	Internal Cobalt Measurements	253
7.1.2	External Radiation Measurements	257
7.2	ENVIRONMENTAL SAMPLES	259
7.2.1	Field Measurements of Cobalt	260
7.2.2	Laboratory Analysis of Environmental Samples	260
7.3	ADEQUACY OF THE DATABASE	266
7.3.1	Identification of Data Needs	266
7.3.2	Ongoing Studies	267

8. REGULATIONS AND ADVISORIES	269
9. REFERENCES	291
10. GLOSSARY	377

APPENDICES

A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
B. USER'S GUIDE	B-1
C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	C-1
D. OVERVIEW OF BASIC RADIATION PHYSICS, CHEMISTRY AND BIOLOGY	D-1

LIST OF FIGURES

3-1.	Levels of Significant Exposure to Cobalt - Chemical Toxicity - Inhalation	38
3-2.	Levels of Significant Exposure to Cobalt - Chemical Toxicity - Oral	65
3-3.	Levels of Significant Exposure to Cobalt - Radiation Toxicity - External	93
3-4.	Transfer Parameters for Cobalt Following Inhalation of Cobalt Oxide (Co_3O_4) Particles, Showing the Fractions of the Lung Content, $L(t)$, and Time, t , Cleared Per Day by Each Route	114
3-5.	Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	129
3-6.	Respiratory Tract Compartments in Which Particles May be Deposited	132
3-7.	Reaction of Gases or Vapors at Various Levels of the Gas-Blood Interface	133
3-8.	Compartment Model to Represent Time-Dependent Particle Transport in the Respiratory Tract	137
3-9.	The Human Respiratory Tract Model: Absorption into Blood	139
3-10.	ICRP Biokinetics Model for Cobalt	141
3-11.	Relation Between Mean Cobalt Exposure and Mean Blood Concentration of Cobalt in Exposed Workers	156
3-12.	Existing Information on Health Effects of Stable Cobalt	162
3-13.	Existing Information on Health Effects of Radioactive Cobalt	163
6-1.	Frequency of NPL Sites with Cobalt Contamination	198
6-2.	Frequency of NPL Sites with Cobalt 60 Contamination	199

LIST OF TABLES

3-1.	Levels of Significant Exposure to Cobalt - Chemical Toxicity - Inhalation	30
3-2.	Levels of Significant Exposure to Cobalt - Chemical Toxicity - Oral	54
3-3.	Levels of Significant Exposure to Cobalt - Chemical Toxicity - Dermal	80
3-4.	Levels of Significant Exposure to Cobalt - Radiation Toxicity - External	82
3-5.	Genotoxicity of Cobalt <i>In Vitro</i>	109
3-6.	Initial (Day 3) Lung Deposits of Cobalt Oxide and Summary of Lung Retention at 90 and 180 Days	116
3-7.	Summary of Measurements of Retention and Excretion After Intragastric Administration of Cobalt Oxide (Co ₃ O ₄) Particles	117
3-8.	Peak Translocation and Average Mechanical Clearance Rates After Inhalation of Cobalt Oxide	123
3-9.	Summary of Measurements of Retention and Excretion of Cobalt Following Injection of Cobalt Nitrate Co(NO ₃) ₂ Solution	126
3-10.	Reference Respiratory Values for a General Caucasian Population at Different Levels of Activity	131
3-11.	Reference Values of Parameters for the Compartment Model to Represent Time-dependent Particle Transport from the Human Respiratory Tract	135
3-12.	Cobalt Exposure Concentrations and Amounts in the Blood and Urine of Subjects Examined	155
4-1.	Chemical Identity of Cobalt and Selected Compounds	176
4-2.	Physical and Chemical Properties of Cobalt and Selected Compounds	180
4-3.	Principal Radioactive Cobalt Isotopes	184
5-1.	Current U.S. Manufacturers of Cobalt Metal and Selected Cobalt Compounds	187
5-2.	Facilities that Produce, Process, or Use Cobalt or Cobalt Compounds	189
6-1.	Releases to the Environment from Facilities that Produce, Process, or Use Cobalt or Cobalt Compounds	203
6-2.	Concentration of Cobalt in the Atmosphere	221
6-3.	Cobalt Levels in Water	225

6-4.	Cobalt Levels in Sediment	229
6-5.	Cobalt Levels in Food	232
6-6.	Cobalt Content of Miscellaneous Substances	235
6-7.	Mean Daily Dietary Intake of Cobalt for Selected Population Groups in Canada	237
6-8.	Cobalt Levels in Human Tissues and Fluids	239
6-9.	Ongoing Studies on Cobalt	251
7-1.	Analytical Methods for Determining Stable Cobalt in Biological Materials	254
7-2.	Analytical Methods for Determining Radioactive Cobalt in Biological Samples	256
7-3.	Analytical Methods for Determining Stable Cobalt in Environmental Samples	261
7-4.	Analytical Methods for Determining Radioactive Cobalt in Environmental Samples	263
7-5.	Ongoing Analytical Studies on Cobalt	268
8-1.	Regulations and Guidelines Applicable to Stable Cobalt	271
8-2.	Regulations and Guidelines Applicable to Radioactive Cobalt	281